Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Monopar Therapeutics Highlights Encouraging Data From Early-Stage Soft Tissue Cancer Study

Published 16/11/2022, 15:09
© Reuters.  Monopar Therapeutics Highlights Encouraging Data From Early-Stage Soft Tissue Cancer Study
MNPR
-

Benzinga -

  • Monopar Therapeutics Inc (NASDAQ: MNPR) released data from its ongoing Phase 1b open-label clinical trial of camsirubicin in advanced soft tissue sarcoma patients.
  • The prior exploratory clinical studies of camsirubicin in cancer patients showed the potential to treat patients with high doses for a year or longer.
  • The preclinical and exploratory clinical studies showed no irreversible heart toxicity with camsirubicin, as seen in doxorubicin, one of the most widely used cancer drugs worldwide.
  • The Phase 1b clinical trial has enrolled 11 patients. 5 of 10 patients have exhibited stable disease at 12 weeks. 1 patient met the criteria for SD at the first CT scan (6 weeks) but unfortunately died due to COVID-19 and was not evaluable at the 12-week CT scan.
  • The ASTS subtype patients achieving stable disease on camsirubicin are in line with those more likely to respond to doxorubicin.
  • The trial is presently at the fourth dose-level cohort (520mg/m2), almost twice the trial's starting dose.
  • No drug-related clinical cardiotoxicity has been observed in any patient. The trial continues to enroll and dose-escalate, as there have been no signs of hitting the maximum tolerated dose.
  • Price Action: MNPR shares are up 0.36% at $2.82 on the last check Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.